These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 19178934

  • 21. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
    Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S.
    Cancer; 2004 Sep 15; 101(6):1455-62. PubMed ID: 15316901
    [Abstract] [Full Text] [Related]

  • 22. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L.
    Gynecol Oncol; 2004 Apr 15; 93(1):34-40. PubMed ID: 15047211
    [Abstract] [Full Text] [Related]

  • 23. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
    Kieback DG, Press MF, McCamant SK, Atkinson EN, Möbus VJ, Runnebaum IB, Kreienberg R, Jones LA.
    Geburtshilfe Frauenheilkd; 1995 Apr 15; 55(4):189-94. PubMed ID: 7789706
    [Abstract] [Full Text] [Related]

  • 24. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N, Mylonas I, Jeschke U, Thaqi A, Kuhn C, Puchner T, Friese K.
    Anticancer Res; 2007 Apr 15; 27(4A):2027-33. PubMed ID: 17649817
    [Abstract] [Full Text] [Related]

  • 25. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, Scambia G.
    Gynecol Oncol; 2005 Sep 15; 98(3):383-9. PubMed ID: 15979129
    [Abstract] [Full Text] [Related]

  • 26. ErbB-3 predicts survival in ovarian cancer.
    Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.
    J Clin Oncol; 2006 Sep 10; 24(26):4317-23. PubMed ID: 16896008
    [Abstract] [Full Text] [Related]

  • 27. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
    Geisler JP, Wiemann MC, Miller GA, Geisler HE.
    Gynecol Oncol; 1996 Mar 10; 60(3):424-7. PubMed ID: 8774651
    [Abstract] [Full Text] [Related]

  • 28. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 29. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma.
    Gehrig PA, Van Le L, Olatidoye B, Geradts J.
    Cancer; 1999 Nov 15; 86(10):2083-9. PubMed ID: 10570435
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue.
    Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies J, Sehouli J, Chekerov R, Dietel M, Denkert C.
    Histopathology; 2011 Nov 15; 59(5):918-27. PubMed ID: 22092403
    [Abstract] [Full Text] [Related]

  • 31. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
    Farinola MA, Gown AM, Judson K, Ronnett BM, Barry TS, Movahedi-Lankarani S, Vang R.
    Int J Gynecol Pathol; 2007 Oct 15; 26(4):375-82. PubMed ID: 17885486
    [Abstract] [Full Text] [Related]

  • 32. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer.
    Ouyang Y, Li D, Pater JL, Levine M.
    Breast Cancer Res Treat; 2005 Jul 15; 92(2):115-23. PubMed ID: 15986120
    [Abstract] [Full Text] [Related]

  • 33. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 15; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 34. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor.
    Kieback DG, McCamant SK, Press MF, Atkinson EN, Gallager HS, Edwards CL, Hajek RA, Jones LA.
    Cancer Res; 1993 Nov 01; 53(21):5188-92. PubMed ID: 8221656
    [Abstract] [Full Text] [Related]

  • 35. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A, Jovanovic D, Jelic S.
    J BUON; 2009 Nov 01; 14(4):635-9. PubMed ID: 20148455
    [Abstract] [Full Text] [Related]

  • 36. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T.
    APMIS; 2009 Sep 01; 117(9):644-50. PubMed ID: 19703124
    [Abstract] [Full Text] [Related]

  • 37. Clinical significance of hormonal receptor status of malignant ovarian tumors.
    Tkalia IG, Vorobyova LI, Svintsitsky VS, Nespryadko SV, Goncharuk IV, Lukyanova NY, Chekhun VF.
    Exp Oncol; 2014 Jun 01; 36(2):125-33. PubMed ID: 24980769
    [Abstract] [Full Text] [Related]

  • 38. [Relationship between hormone therapy in women with ovarian malignancy and prognosis].
    Li L, Pan ZM, Chen XQ, Gao K, Zhang W, Luo Y, Yao ZQ, Liang XQ, Huang W, Yao DS.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov 01; 43(11):843-8. PubMed ID: 19087569
    [Abstract] [Full Text] [Related]

  • 39. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
    Bird PA, Hill AG, Houssami N.
    Ann Surg Oncol; 2008 Jul 01; 15(7):1983-8. PubMed ID: 18408976
    [Abstract] [Full Text] [Related]

  • 40. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
    De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, Gonçalves WJ.
    Oncol Rep; 2007 Jul 01; 18(1):25-32. PubMed ID: 17549341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.